Tyro Payments analysis: Fair value $1.66 vs current $1.20 (38% upside). Health market leader (25% share) expanding into banking and new verticals. CEO transition risk balanced by strong balance sheet.
View noteTuas Limited analysis: Fair value S$6.82 vs current S$6.89. M1 acquisition creates 32% market share with S$103m synergies. Medium-high risk, 13% expected returns.
View noteTrajan Group Holdings trades at $0.76 versus $1.64 fair value, offering 116% upside through operational leverage and innovation commercialisation in analytical instrumentation markets.
View noteTPG Telecom analysis: Partnership-enabled transformation creating competitive advantages. Fair value $11.97 vs current $5.17. Strong financial health, narrow moat, medium risk.
View noteAustralia's leading government ERP SaaS provider with 21% ARR growth, 42.3% EBITDA margins, trading at $39.01 versus $53.32 fair value, offering 37% upside through SaaS+ model scaling and UK expansion validation.
View noteTelix Pharmaceuticals analysis: Fair value $17.14 USD vs current $17.50 AUD. High-growth radiopharmaceutical platform with 51.2% revenue growth, therapeutic pipeline worth $2.8bn risk-adjusted value, though execution risks and 8.4x leverage require careful assessment.
View noteHOLD rating with $3.81 fair value vs $4.21 current price. Strong growth prospects offset by integration risks and margin compression pressures.
View noteHOLD rating with $11.59 fair value vs $14.00 current price. Strong infrastructure franchise but elevated leverage and regulatory risks limit upside potential.
View noteSouthern Cross Austereo analysis: BUY rating, $3.15 fair value vs $0.84 current price. Digital transformation progressing with LiSTNR profitability achieved.
View noteAustralia's largest TV broadcaster trades at $0.15 vs fair value $0.45, leveraging AFL rights and 7plus digital growth amid advertising headwinds and global platform competition.
View noteSuper Retail Group trades at $16.21 vs fair value $13.56, facing digital disruption and margin pressure across four-brand specialty retail portfolio with 55% thesis failure probability.
View noteBUY rating with $1.04 fair value vs $0.54 current price. High-risk transformation story with 562% EBITDA growth but execution challenges.
View note